Thrombolytic therapy for deep vein thrombosis.

Area of Science:

• Vascular Medicine
• Thrombosis Management
• Medical Interventions

Background:

• Acute deep vein thrombosis (DVT) requires effective treatment to prevent complications.
• Current treatments include anticoagulation with heparin and thrombolytic therapy.
• Both treatment modalities carry inherent risks, notably bleeding.

Purpose of the Study:

• To outline a preferred treatment strategy for acute DVT using thrombolytic agents.
• To compare the long-term efficacy of thrombolytic therapy versus heparin for DVT.
• To evaluate the impact of treatment on deep venous system restoration.

Main Methods:

• Review and preference for thrombolytic agents in acute DVT cases without contraindications.
• Comparison of short-term (6 months) and long-term outcomes between thrombolysis and heparin.
• Consideration of results from prospective, randomized studies.

Main Results:

• Short-term results (first 6 months) for thrombolytic therapy and heparin are comparable.
• Thrombolytic therapy is favored for potentially superior long-term anatomical and physiological restoration of the deep venous system.
• Prospective studies show improved long-term venous function with thrombolytic therapy compared to anticoagulation.

Conclusions:

• Thrombolytic agents are recommended for acute DVT treatment when no contraindications exist.
• Thrombolysis offers better prospects for long-term venous system recovery than heparin alone.
• Improved long-term venous function is a key benefit of thrombolytic therapy in DVT management.